Serina Therapeutics Announces Dr. Randall Moreadith, President and CEO, Will Serve As a Panelist at the Annual Neuretech Investing and Partnership Conference in Boston, MA on May 21-22, 2019

Huntsville, AL, May 20th 2019

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that Dr. Randall Moreadith will serve as a panelist in the “Parkinson’s and Movement Disorders” session at the annual Neuretech Investing and Partnership conference in Boston May 21-22, 2019.

“I am delighted that the exceptional work we are performing at Serina Therapeutics continues to be highlighted at major conferences in the neurosciences,” stated Dr. Moreadith. “The annual Neuretech Investing and Partnership conference brings together cutting-edge companies and investors that are developing pharmaceuticals and devices addressing unmet needs in Parkinson’s, pain, Alzheimer’s and psychiatry. I look forward to updating the attendees this year on our programs in Parkinson’s disease.”

Serina Therapeutics Pipeline

Serina Therapeutics has a robust pipeline of POZ™ polymer conjugates. The most advanced is SER-214, a first-in-class drug candidate that delivers rotigotine continuously following a single weekly subcutaneous administration. The Phase Ia program in patients with Parkinson’s disease has completed enrollment, and Serina plans to advance SER-214 into Phase Ib/II development in 2019 for both Parkinson’s disease and restless leg syndrome. In addition to this product candidate for early Parkinson’s disease, Serina is poised to advance POZ-apomorphine – a polymer conjugate of apomorphine, the most potent dopamine agonist known – for advanced disease. Serina is on track to advance this product candidate into Phase I development in 1H-2020. POZ-apomorphine will be developed for patients with advancing Parkinson’s disease who have significant daily “off” periods not controlled with optimal oral therapy. POZ-apomorphine is designed to deliver apomorphine continuously over a one-week period following a single SC injection, and early studies in the monkey show this occurs without any skin issues. Inflammatory skin reactions, including abscess formation, can occur with the current formulations of apomorphine that are administered as a daily 12-16 hour infusion (example – APO-Go). These formulations lead to a high incidence of nodule formation.

In addition to a growing pipeline of proprietary programs focused on movement disorders, pain and epilepsy Serina seeks partnership opportunities with pharmaceutical companies to further unlock the promise of the POZ™ platform.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that is developing novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products
for various pharmaceutical partners. POZ™ technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.